77
Participants
Start Date
September 3, 2018
Primary Completion Date
August 19, 2020
Study Completion Date
January 18, 2022
Penicillamine (D1-W12)
Penicillamine during baseline period (D1-W12)
TETA 4HCL (W12-60)
TETA 4HCL during post randomisation and 1st extension period (W12-W60)
Penicillamine (W12-W60)
Penicillamine during rondomisation and 1st extension period period (W12-W60)
TETA 4HCL (60-<W108)
TETA 4HCL during 2nd extension period (W60-\<W108)
A.O. San Paolo Milano, Milan
DiSCOG Gastroenterology Unit, Padua
Innere Medizin, Heidelberg
Hospital mother children, Bron
Centre National de Référence Wilson, Hôpital Lariboisière, Paris
Poliklinik Hepatologie/Transplantationsambulanz, Munich
Yale University School of Medicine, New Haven
KU Leuven, Department of Clinical and Experimental Medicine, Leuven
Hospital Nossa Senhora das Graças (HNSG), Curitiba
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo
Hepato-gastroenterologisk afd, Aarhus
Nucleo de Pesquisa e Desenvolvimento de Medicamentos - Universidade Federal do Ceará - Rodolfo Teófilo, Fortaleza
Institute of Psychiatry and Neurology, Warsaw
University of Surrey, Department of Clinical and Experimental Medicine, Guildford
Leeds Teaching Hospitals NHS Trust, Leeds
Lead Sponsor
Orphalan
INDUSTRY